Advertisement

Gynecological and Reproductive Complications in Primary Sjögren’s Syndrome

  • Andreas V. Goules
  • Athanasios G. Tzioufas
Chapter

Abstract

Primary Sjögren’s syndrome (SS) almost exclusively afflicts women. The external genitalia are commonly affected and as a result, vaginal dryness and dypareunia may occur. Other less common gynecological problems have also been described.

Keywords

Congenital Hypothyroidism Vaginal Dryness Congenital Heart Block Subacute Cutaneous Lupus Erythematosus Complete Congenital Heart Block 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1.  1. 
    Capriello P, Barale E, Cappelli N, Lupo S, Teti G. Sjogren’s syndrome: clinical, cytological, histological and colposcopic aspects in women. Clin Exp Obstet Gynecol. 1988;15:9–12.PubMedGoogle Scholar
  2.  2. 
    Skopouli FN, Papanikolaou S, Malamou-Mitsi V, Papanikolaou N, Moutsopoulos HM. Obstetric and gynaecological profile in patients with primary Sjogren’s syndrome. Ann Rheum Dis. 1994;53:569–73.PubMedCrossRefGoogle Scholar
  3.  3. 
    Mulherin DM, Sheeran TP, Kumararatne DS, Speculand B, Luesley D, Situnayake RD. Sjogren’s syndrome in women presenting with chronic dyspareunia. Br J Obstet Gynaecol. 1997;104:1019–23.PubMedCrossRefGoogle Scholar
  4.  4. 
    Cirpan T, Guliyeva A, Onder G, Terek MC, Ozsaran A, Kabasakal Y, et al. Comparison of human papillomavirus testing and cervical cytology with colposcopic examination and biopsy in cervical cancer screening in a cohort of patients with Sjogren’s syndrome. Eur J Gynaecol Oncol. 2007;28:302–6.PubMedGoogle Scholar
  5.  5. 
    Marchesoni D, Mozzanega B, De Sandre P, Romagnolo C, Gambari PF, Maggino T. Gynaecological aspects of primary Sjogren’s syndrome. Eur J Obstet Gynecol Reprod Biol. 1995;63:49–53.PubMedCrossRefGoogle Scholar
  6.  6. 
    Haga HJ, Gjesdal CG, Irgens LM, Ostensen M. Reproduction and gynaecological manifestations in women with primary Sjogren’s syndrome: a case-control study. Scand J Rheumatol. 2005;34:45–8.PubMedCrossRefGoogle Scholar
  7.  7. 
    Boh EE. Neonatal lupus erythematosus. Clin Dermatol. 2004;22:125–8.PubMedCrossRefGoogle Scholar
  8.  8. 
    Brucato A, Cimaz R, Caporali R, Ramoni V, Buyon J. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol. 2011;40(1):27–41.PubMedCrossRefGoogle Scholar
  9.  9. 
    Buyon JP, Brucato A, Friedman DM. What’s in a name? Ann Rheum Dis. 2008;67:732; discussion 732.PubMedCrossRefGoogle Scholar
  10. 10.
    Routsias JG, Tzioufas AG. Sjogren’s syndrome – study of autoantigens and autoantibodies. Clin Rev Allergy Immunol. 2007;32:238–51.PubMedCrossRefGoogle Scholar
  11. 11.
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Siren MK, Julkunen H, Kaaja R. The increasing incidence of isolated congenital heart block in Finland. J Rheumatol. 1998;25:1862–4.PubMedGoogle Scholar
  13. 13.
    Michaelsson M, Engle MA. Congenital complete heart block: an international study of the natural history. Cardiovasc Clin. 1972;4:85–101.PubMedGoogle Scholar
  14. 14.
    Lee LA. Neonatal lupus erythematosus. J Invest Dermatol. 1993;100:9S–13S.PubMedCrossRefGoogle Scholar
  15. 15.
    Sontheimer RD, Maddison PJ, Reichlin M, Jordon RE, Stastny P, Gilliam JN. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med. 1982;97:664–71.PubMedGoogle Scholar
  16. 16.
    Sontheimer RD, McCauliffe DP. Pathogenesis of anti-Ro/SS-A autoantibody-associated cutaneous lupus erythematosus. Dermatol Clin. 1990;8:751–8.PubMedGoogle Scholar
  17. 17.
    Watson R, Kang JE, May M, Hudak M, Kickler T, Provost TT. Thrombocytopenia in the neonatal lupus syndrome. Arch Dermatol. 1988;124:560–3.PubMedCrossRefGoogle Scholar
  18. 18.
    Kanagasegar S, Cimaz R, Kurien BT, Brucato A, Scofield RH. Neonatal lupus manifests as isolated neutropenia and mildly abnormal liver functions. J Rheumatol. 2002;29:187–91.PubMedGoogle Scholar
  19. 19.
    Laxer RM, Roberts EA, Gross KR, Britton JR, Cutz E, Dimmick J, et al. Liver disease in ­neonatal lupus erythematosus. J Pediatr. 1990;116:238–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr. 2003;142:678–83.PubMedCrossRefGoogle Scholar
  21. 21.
    Ross G, Sammaritano L, Nass R, Lockshin M. Effects of mothers’ autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med. 2003;157:397–402.PubMedCrossRefGoogle Scholar
  22. 22.
    Boros CA, Spence D, Blaser S, Silverman ED. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum. 2007;57:261–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Schmidt KG, Ulmer HE, Silverman NH, Kleinman CS, Copel JA. Perinatal outcome of fetal complete atrioventricular block: a multicenter experience. J Am Coll Cardiol. 1991;17:1360–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Fesslova V, Vignati G, Brucato A, De Sanctis M, Butera G, Pisoni MP, et al. The impact of treatment of the fetus by maternal therapy on the fetal and postnatal outcomes for fetuses diagnosed with isolated complete atrioventricular block. Cardiol Young. 2009;19:282–90.PubMedCrossRefGoogle Scholar
  25. 25.
    Moak JP, Barron KS, Hougen TJ, Wiles HB, Balaji S, Sreeram N, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol. 2001;37:238–42.PubMedCrossRefGoogle Scholar
  26. 26.
    Udink ten Cate FE, Breur JM, Cohen MI, Boramanand N, Kapusta L, Crosson JE, et al. Dilated cardiomyopathy in isolated congenital complete atrioventricular block: early and long-term risk in children. J Am Coll Cardiol. 2001;37:1129–34.PubMedCrossRefGoogle Scholar
  27. 27.
    Nield LE, Silverman ED, Smallhorn JF, Taylor GP, Mullen JB, Benson LN, et al. Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block. J Am Coll Cardiol. 2002;40:796–802.PubMedCrossRefGoogle Scholar
  28. 28.
    Brucato A, Cimaz R, Catelli L, Meroni P. Anti-Ro-associated sinus bradycardia in newborns. Circulation. 2000;102:E88–9.PubMedGoogle Scholar
  29. 29.
    Cimaz R, Stramba-Badiale M, Brucato A, Catelli L, Panzeri P, Meroni PL. QT interval prolongation in asymptomatic anti-SSA/Ro-positive infants without congenital heart block. Arthritis Rheum. 2000;43:1049–53.PubMedCrossRefGoogle Scholar
  30. 30.
    Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, Huong DL, Denjoy I, Vauthier D, et al. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum. 2004;50:3187–94.PubMedCrossRefGoogle Scholar
  31. 31.
    Friedman DM, Kim MY, Copel JA, Davis C, Phoon CK, Glickstein JS, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation. 2008;117:485–93.PubMedCrossRefGoogle Scholar
  32. 32.
    Cuneo BF, Strasburger JF, Niksch A, Ovadia M, Wakai RT. An expanded phenotype of maternal SSA/SSB antibody-associated fetal cardiac disease. J Matern Fetal Neonatal Med. 2009;22:233–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med. 1994;120:544–51.PubMedGoogle Scholar
  34. 34.
    Press J, Uziel Y, Laxer RM, Luy L, Hamilton RM, Silverman ED. Long-term outcome of mothers of children with complete congenital heart block. Am J Med. 1996;100:328–32.PubMedCrossRefGoogle Scholar
  35. 35.
    Rivera TL, Izmirly PM, Birnbaum BK, Byrne P, Brauth JB, Katholi M, et al. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis. 2009;68:828–35.PubMedCrossRefGoogle Scholar
  36. 36.
    Brucato A, Gasparini M, Vignati G, Riccobono S, De Juli E, Quinzanini M, et al. Isolated congenital complete heart block: longterm outcome of children and immunogenetic study. J Rheumatol. 1995;22:541–3.PubMedGoogle Scholar
  37. 37.
    Martin V, Lee LA, Askanase AD, Katholi M, Buyon JP. Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis Rheum. 2002;46:2377–83.PubMedCrossRefGoogle Scholar
  38. 38.
    Sonesson SE, Salomonsson S, Jacobsson LA, Bremme K, Wahren-Herlenius M. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum. 2004;50:1253–61.PubMedCrossRefGoogle Scholar
  39. 39.
    Rein AJ, Mevorach D, Perles Z, Gavri S, Nadjari M, Nir A, et al. Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogram-based study. Circulation. 2009;119:1867–72.PubMedCrossRefGoogle Scholar
  40. 40.
    Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum. 2001;44:1832–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Gladman G, Silverman ED, Yuk L, Luy L, Boutin C, Laskin C, et al. Fetal echocardiographic screening of pregnancies of mothers with anti-Ro and/or anti-La antibodies. Am J Perinatol. 2002;19:73–80.PubMedCrossRefGoogle Scholar
  42. 42.
    Gerosa M, Cimaz R, Stramba-Badiale M, Goulene K, Meregalli E, Trespidi L, et al. Electrocardiographic abnormalities in infants born from mothers with autoimmune diseases – a multicentre prospective study. Rheumatology (Oxford). 2007;46:1285–9.CrossRefGoogle Scholar
  43. 43.
    Gordon P, Khamashta MA, Rosenthal E, Simpson JM, Sharland G, Brucato A, et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol. 2004;31:2480–7.PubMedGoogle Scholar
  44. 44.
    Salomonsson S, Sonesson SE, Ottosson L, Muhallab S, Olsson T, Sunnerhagen M, et al. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med. 2005;201:11–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Izmirly PM, Llanos C, Lee LA, Askanase A, Kim MY, Buyon JP. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum. 2010;62:1153–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Spence D, Hornberger L, Hamilton R, Silverman ED. Increased risk of complete congenital heart block in infants born to women with hypothyroidism and anti-Ro and/or anti-La antibodies. J Rheumatol. 2006;33:167–70.PubMedGoogle Scholar
  47. 47.
    Llanos C, Izmirly PM, Katholi M, Clancy RM, Friedman DM, Kim MY, et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum. 2009;60:3091–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Strandberg L, Winqvist O, Sonesson SE, Mohseni S, Salomonsson S, Bremme K, et al. Antibodies to amino acid 200–239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clin Exp Immunol. 2008;154:30–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Stea EA, Routsias JG, Clancy RM, Buyon JP, Moutsopoulos HM, Tzioufas AG. Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum. 2006;54:2228–34.PubMedCrossRefGoogle Scholar
  50. 50.
    James TN. Normal and abnormal consequences of apoptosis in the human heart: from postnatal morphogenesis to paroxysmal arrhythmias. Circulation. 1994;90:556–73.PubMedGoogle Scholar
  51. 51.
    Miranda-Carus ME, Askanase AD, Clancy RM, Di Donato F, Chou TM, Libera MR, et al. Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of TNF-alpha by macrophages. J Immunol. 2000;165:5345–51.PubMedGoogle Scholar
  52. 52.
    Clancy RM, Buyon JP. Clearance of apoptotic cells: TGF-beta in the balance between inflammation and fibrosis. J Leukoc Biol. 2003;74:959–60.PubMedCrossRefGoogle Scholar
  53. 53.
    Clancy RM, Neufing PJ, Zheng P, O’Mahony M, Nimmerjahn F, Gordon TP, et al. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest. 2006;116:2413–22.PubMedGoogle Scholar
  54. 54.
    Clancy RM, Backer CB, Yin X, Kapur RP, Molad Y, Buyon JP. Cytokine polymorphisms and histologic expression in autopsy studies: contribution of TNF-alpha and TGF-beta 1 to the pathogenesis of autoimmune-associated congenital heart block. J Immunol. 2003;171:3253–61.PubMedGoogle Scholar
  55. 55.
    Jaeggi ET, Fouron JC, Silverman ED, Ryan G, Smallhorn J, Hornberger LK. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation. 2004;110:1542–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Theander E, Brucato A, Gudmundsson S, Salomonsson S, Wahren-Herlenius M, Manthorpe R. Primary Sjogren’s syndrome – treatment of fetal incomplete atrioventricular block with dexamethasone. J Rheumatol. 2001;28:373–6.PubMedGoogle Scholar
  57. 57.
    Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum. 1999;42:2335–45.PubMedCrossRefGoogle Scholar
  58. 58.
    Lopes LM, Tavares GM, Damiano AP, Lopes MA, Aiello VD, Schultz R, et al. Perinatal outcome of fetal atrioventricular block: one-hundred-sixteen cases from a single institution. Circulation. 2008;118:1268–75.PubMedCrossRefGoogle Scholar
  59. 59.
    Breur JM, Visser GH, Kruize AA, Stoutenbeek P, Meijboom EJ. Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature. Ultrasound Obstet Gynecol. 2004;24:467–72.PubMedCrossRefGoogle Scholar
  60. 60.
    Brucato A, Astori MG, Cimaz R, Villa P, Li Destri M, Chimini L, et al. Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to high-dose dexamethasone in utero. Ann Rheum Dis. 2006;65:1422–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Kaaja R, Julkunen H. Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al. Arthritis Rheum. 2003;48:280–1; author reply 281–282.PubMedCrossRefGoogle Scholar
  62. 62.
    Kaaja R, Julkunen H, Ammala P, Teppo AM, Kurki P. Congenital heart block: successful prophylactic treatment with intravenous gamma globulin and corticosteroid therapy. Am J Obstet Gynecol. 1991;165:1333–4.PubMedGoogle Scholar
  63. 63.
    Pisoni CN, Brucato A, Ruffatti A, Espinosa G, Cervera R, Belmonte-Serrano M, et al. Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study. Arthritis Rheum. 2010;62:1147–52.PubMedCrossRefGoogle Scholar
  64. 64.
    Friedman DM, Llanos C, Izmirly PM, Brock B, Byron J, Copel J, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum. 2010;62: 1138–46.PubMedCrossRefGoogle Scholar
  65. 65.
    Matsubara S, Morimatsu Y, Shiraishi H, Kuwata T, Ohkuchi A, Izumi A, et al. Fetus with heart failure due to congenital atrioventricular block treated by maternally administered ritodrine. Arch Gynecol Obstet. 2008;278:85–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Izmirly PM, Kim MY, Llanos C, Le PU, Guerra MM, Askanase AD, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis. 2010;69(10):1827–30.PubMedCrossRefGoogle Scholar
  67. 67.
    Routsias JG, Kyriakidis NC, Friedman DM, Llanos C, Clancy R, Moutsopoulos HM, Buyon J, Tzioufas AG. Association of idiotypic/anti-idiotypic antibody ratio with therapeutic response of IVIG in the prevention of recurrent autoimmune associated congenital heart block. Arthritis Rheum. 2011 May 25. doi: 10.1002/art.30464. [Epub ahead of print]Google Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Andreas V. Goules
    • 1
  • Athanasios G. Tzioufas
    • 1
  1. 1.Department of Pathophysiology, School of MedicineUniversity of AthensAthensGreece

Personalised recommendations